Response Letter to "Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China"

被引：0
作者：
Guan, Haijing [1 ]
Sheng, Yanan [2 ]
Guo, Wanjie [3 ]
Han, Sheng [3 ]
Shi, Luwen [1 ]
机构：
[1] Peking Univ, Sch Pharmaceut Sci, Beijing, Peoples R China
[2] Peking Univ, China Ctr Hlth Econ Res, Beijing, Peoples R China
[3] Peking Univ, Int Res Ctr Med Adm, Beijing, Peoples R China
来源：
ADVANCES IN THERAPY | 2020年 / 37卷 / 02期
关键词：
Alectinib; ALK; China; Cost-Effectiveness; NSCLC; CRIZOTINIB;
D O I：
10.1007/s12325-019-01202-2
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：971 / 972
页数：2
相关论文
共 5 条
  • [1] Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK plus NSCLC.
    Camidge, D. Ross
    Peters, Solange
    Mok, Tony
    Gadgeel, Shirish M.
    Cheema, Parneet K.
    Pavlakis, Nick
    De Marinis, Filippo
    Stroyakovskiy, Daniil L.
    Cho, Byoung Chul
    Zhang, Li
    Moro-Sibilot, Denis
    Zeaiter, Ali Hassan
    Mitry, Emmanuel
    Balas, Bogdana
    Mueller, Barbara
    Shaw, Alice
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer
    Carlson, Josh J.
    Suh, Kangho
    Orfanos, Panos
    Wong, William
    [J]. PHARMACOECONOMICS, 2018, 36 (04) : 495 - 504
  • [3] Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
    Hida, Toyoaki
    Nokihara, Hiroshi
    Kondo, Masashi
    Kim, Young Hak
    Azuma, Koichi
    Seto, Takashi
    Takiguchi, Yuichi
    Nishio, Makoto
    Yoshioka, Hiroshige
    Imamura, Fumio
    Hotta, Katsuyuki
    Watanabe, Satoshi
    Goto, Koichi
    Satouchi, Miyako
    Kozuki, Toshiyuki
    Shukuya, Takehito
    Nakagawa, Kazuhiko
    Mitsudomi, Tetsuya
    Yamamoto, Nobuyuki
    Asakawa, Takashi
    Asabe, Ryoichi
    Tanaka, Tomohiro
    Tamura, Tomohide
    [J]. LANCET, 2017, 390 (10089) : 29 - 39
  • [4] Survival Analysis for Economic Evaluations Alongside Clinical Trials-Extrapolation with Patient-Level Data: Inconsistencies, Limitations, and a Practical Guide
    Latimer, Nicholas R.
    [J]. MEDICAL DECISION MAKING, 2013, 33 (06) : 743 - 754
  • [5] Zhou C, 2018, ANN ONCOL, V29, P18
1